Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences:
1. The Mizuho Neuro & Ophthalmology Summit 2025, where management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET
2. The Jefferies Global Healthcare Conference, featuring a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and accessible through the company's investor relations website, with a replay available for 90 days following the event.
Collegium Pharmaceutical (NASDAQ: COLL) has announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC. This ASR is part of a larger $150 million share repurchase program authorized in January 2024, with $65 million remaining after this transaction. The company will receive an initial delivery of 692,281 shares at $28.89 per share, representing approximately 80% of expected total shares under the ASR.
The company reported strong Q1 2025 performance with 23% year-over-year revenue growth, driven by its pain portfolio and ADHD medicine Jornay PM®. The final settlement of the ASR is expected by Q3 2025, with the final share count based on volume-weighted average prices. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
Investors can access the conference call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. An audio webcast will be available through the Investors section of Collegium's website and will remain accessible for replay approximately two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in the 24th Annual Needham Healthcare Conference, which will be held virtually from April 7-10, 2025. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 9:30 a.m. ET.
The fireside discussion will be accessible through a live webcast on the Investors section of Collegium's website. Interested parties can view the presentation at https://ir.collegiumpharma.com, and a replay will remain available on the company's website for 90 days following the event.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming presentation of four posters featuring real-world patient data from its pain management portfolio at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting in Austin, TX, from April 3-6, 2025.
A notable highlight is their poster on 'Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids,' which has been selected as a top abstract and will be published in AAPM's Pain Medicine Journal. The presentations will focus on their key products, including BELBUCA® (buprenorphine buccal film) and Xtampza® ER (oxycodone), both prescribed for severe pain management requiring daily, long-term opioid treatment.
Dr. Thomas Smith, Chief Medical Officer, emphasized the significance of presenting meaningful real-world data for healthcare professionals treating pain patients, reinforcing Collegium's position as a leader in responsible pain management.
Collegium Pharmaceutical (COLL) announced significant changes to its Board of Directors and executive leadership team. Founder and Chairman Michael Heffernan and Board Member Gwen A. Melincoff will retire at the Annual General Meeting on May 15, 2025. Gino Santini, current Lead Independent Director, will become Chairman, while Dr. Carlos Paya will be nominated to the Board.
The company also appointed three new executive leaders: David Dieter as Executive VP and General Counsel, Jane Gonnerman as Executive VP of Strategy and Corporate Development, and Dean J. Patras as Chief People Officer. These appointments come as Collegium enters a new growth phase focused on accelerating momentum for Jornay PM, maximizing its pain portfolio, and strategic capital deployment.
Collegium Pharmaceutical (Nasdaq: COLL) announced two poster presentations featuring real-world data for its ADHD treatment Jornay PM (methylphenidate HCl) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference in Chicago from March 10-13, 2025.
The presentations, which will showcase real-world benefits of Jornay PM as a therapeutic option for the ADHD community, will be displayed in the Riverside Center Exhibit Hall during specific exhibition hours on March 10-11, 2025. Chief Medical Officer Thomas Smith emphasized the company's commitment to providing differentiated medicines for serious medical conditions.
The PR highlights that ADHD is one of the most common childhood psychiatric conditions, typically diagnosed in childhood and potentially continuing into adulthood, with symptoms including attention difficulties, impulsive behaviors, and hyperactivity, particularly during early morning routines.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its upcoming participation in three major healthcare investor conferences in March 2025. The company's management will engage in investor meetings at the Leerink Partners 2025 Global Healthcare Conference on March 11, the Jefferies Biotech on the Beach Summit on March 12, and the Barclays 27th Annual Global Healthcare Conference on March 13.
Collegium Pharmaceutical reported strong financial results for Q4 and full-year 2024. The company achieved record quarterly revenue of $181.9 million (up 22% YoY) and full-year revenue of $631.4 million (up 11% YoY). Q4 GAAP net income was $12.5 million with record adjusted EBITDA of $107.7 million.
Key product performance included Jornay PM with Q4 net revenue of $29.3 million and pro forma full-year revenue of $100.7 million, showing 29% YoY prescription growth. Belbuca achieved record quarterly revenue of $55.2 million (up 12% YoY), while Xtampza ER posted record revenue of $51.5 million (up 6% YoY).
The company ended 2024 with $162.8 million in cash and equivalents, after completing the $200 million Ironshore Therapeutics acquisition and executing $60 million in share repurchases.